Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Lexicon Pharmaceuticals' Stock Exploded Higher in August

By George Budwell - Sep 10, 2015 at 8:17AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Lexicon Pharmaceuticals' long-awaited success in a pivotal late-stage trial sent shares soaring in August.

What: Lexicon Pharmaceuticals (LXRX 5.99%) continued its seemingly life-long habit of going against the market last August -- with the stock gaining over 40%, as per data from S&P Capital IQ, while the entire biotech industry as a whole fell by double digits:

LXRX Chart

Lexicon's good fortune last month was due to the company's experimental drug, oral telotristat etiprate, reportedly meeting its primary endpoint in a pivotal late-stage trial as a potential treatment for cancer patients with carcinoid syndrome not adequately controlled by the current standard of care.

Specifically, Lexicon said that the 250 mg and 500 mg doses of oral telotristat etiprate both led to significantly lower incidences of daily bowel movements in the 12-week study. Carcinoid syndrome is described as a rare disorder that affects patients with neuroendocrine tumors, often triggering severe bouts of diarrhea. 

So what: Lexicon has lingered in the clinical-stage biotech wilderness for over two decades at this point because of its inability to develop a commercial product. With this late-stage success, however, this rather lengthy drought appears to be at an end.

Now what: Lexicon plans on filing for the drug's regulatory approval with the U.S. Food and Drug Administration soon, meaning that it could be on the market sometime next year. Unfortunately, I think telotristat's approval is already baked into Lexicon's share price for the most part, given that the company now sports a hefty $1.2 billion market cap following this run-up, despite the fact that the company is expected to remain cash flow negative for the foreseeable future.

Although Lexicon does have another clinical candidate, sotagliflozin, indicated for Type 1 and 2 diabetes, I think investors may ultimately want to take a wait-and-see approach with this high flying biotech for the moment to let its remaining assets mature a bit further before buying shares. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lexicon Pharmaceuticals, Inc. Stock Quote
Lexicon Pharmaceuticals, Inc.
LXRX
$1.77 (5.99%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.